CTAG1A and neoplasm: In intrahepatic cholangiocarcinoma, they were detected in 18.4% of patients, a value significantly higher than that of patients with chronic hepatitis B. Serum NY-ESO-1 antibodies were positively correlated with tumor differentiation, lymphatic metastasis, cTNM stage, and abdominal pain.